TETRAXETAN
SCLC
Y-mAbs TherapeuticsSmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
17 Active assets in the SCLC cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
pm8002 Biotheus Inc. | Phase 3 | B |
zl-1310 Amgen | Phase 3 | B |
gw786034 Samsung Medical Center | Phase 2 | B |
Npi-2358 Xiaorong Dong | Phase 2 | B |
FLUDEOXYGLUCOSE National Cancer Institute (NCI) | Phase 3 | B |
View all 20 →
Same molecule, other indications
TETRAXETAN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →